drugset / Trial / NCT03251612

Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

NCT03251612

Phase 2 Completed 90 enrolled Vejle Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.

Timeline

Start
2017-09-22
Primary completion
2021-08-23
Completion
2022-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject Capecitabine Small molecule
Subject Cetuximab Monoclonal antibody
Subject Irinotecan Small molecule
Subject Oxaliplatin Small molecule
Subject Panitumumab Monoclonal antibody
Subject Regorafenib Small molecule
Subject TAS-102 Small molecule
Subject fluorouracil Small molecule

Indications